MedTrace Logo

Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke

NCT02828540 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-10-02

No results posted yet for this study

Summary

To assess the efficacy and to evaluate safety of HT047 in patients with acute ischemic stroke

Conditions

Interventions

DRUG

HT047 High-dose group

HT047 2250mg, three times a day dosing schedule, 3 tablets per dose

DRUG

HT047 Low-dose group

HT047 1500mg, three times a day dosing schedule, 3 tablets per dose

DRUG

Placebo

placebo having the same appearance as HT047 Tab. 250mg

Sponsors & Collaborators

  • Hocheol Kim

    lead OTHER

Principal Investigators

  • Dae-Il Chang · Kyung Hee University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-04
Primary Completion
2018-08-03
Completion
2018-08-03

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02828540 on ClinicalTrials.gov